drugset / Trial / NCT03213587
Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who failed prior platinum based chemotherapy
Timeline
- Start
- 2017-07-01
- Primary completion
- 2020-07
- Completion
- 2020-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | 500 mg | Oral |